PuSH - Publication Server of Helmholtz Zentrum München: The iminosugar AMP-DNM improves satiety and activates brown adipose tissue through GLP1.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Herrera Moro Chao, D.* ; Wang, Y.* ; Foppen, E.* ; Ottenhoff, R.* ; van Roomen, C.* ; Parlevliet, E.T.* ; van Eijk, M.J.T.* ; Verhoek, M.* ; Boot, R.* ; Marques, A.R.* ; Scheij, S.* ; Mirzaian, M.* ; Kooijman, S.* ; Jansen, K.* ; Wang, D.* ; Mergen, C. ; Seeley, R.J.* ; Tschöp, M.H. ; Overkleeft, H.* ; Rensen, P.C.N.* ; Kalsbeek, A.* ; Aerts, J.M.F.G.* ; Yi, C.X.*

The iminosugar AMP-DNM improves satiety and activates brown adipose tissue through GLP1.

Diabetes 68, 2223-2234 (2019)

Publ. Version/Full Text

Postprint

Research data

DOI

	Open Access Green

Abstract
Metrics
Extra information

Obesity is taking on worldwide epidemic proportions, yet effective pharmacological agents with long-term efficacy remain unavailable. Previously, we designed the iminosugar N-adamantine-methyloxypentyl-deoxynojirimycin (AMP-DNM), which potently improves glucose homeostasis by lowering excessive glycosphingolipids. Here we show that AMP-DNM promotes satiety and activates brown adipose tissue (BAT) in obese rodents. Moreover, we demonstrate that the mechanism mediating these favorable actions depends on oral, but not central, administration of AMP-DNM, which ultimately stimulates systemic glucagon-like peptide 1 (GLP1) secretion. We evidence an essential role of brain GLP1 receptors (GLP1r), as AMP-DNM fails to promote satiety and activate BAT in mice lacking the brain GLP1r as well as in mice treated intracerebroventricularly with GLP1r antagonist exendin-9. In conclusion, AMP-DNM markedly ameliorates metabolic abnormalities in obese rodents by restoring satiety and activating BAT through central GLP1r, while improving glucose homeostasis by mechanisms independent of central GLP1r.

Impact Factor

Scopus SNIP

Scopus
Cited By

Altmetric

7.199

1.796